Previous 10 | Next 10 |
The following slide deck was published by Natera, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Natera (NASDAQ: NTRA ): Q1 GAAP EPS of -$0.45 beats by $0.12 . More news on: Natera, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN CARLOS, Calif. , May 6, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent business progress. Recent...
SAN CARLOS, Calif. , May 4, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the achievement of key recruitment milestones in the ProActive registry study and success in the Prospera early access program....
Warren Buffett will issue his annual letter and hold a virtual shareholder meeting ( BRK.A , BRK.B ) this Saturday, 5/2. More news on: Berkshire Hathaway Inc., Berkshire Hathaway Inc., BridgeBio Pharma, Inc., Notable Calls, , Read more ...
SAN CARLOS, Calif. , April 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2020 , after the market close on May 6, 2020 . Natera will h...
Natera ( NTRA ) has emerged as a rapidly growing company with seven commercialized molecular diagnostic tests targeting key markets of reproductive health, organ transplantation, and oncology. The company enjoys a leadership position in the reproductive health segment, which is almost entirely...
CareDx ( CDNA ) is a precision medicine company focused on the ever-growing transplant diagnostics market. The ongoing COVID-19 pandemic has had a significant negative impact on the stock. The stock fell from $21.15 on January 2 all the way down to $13.94 on March 18. The stock has recovered a...
SAN CARLOS, Calif. , April 15, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today asserted three recently issued oncology patents against ArcherDX in its ongoing patent infringement action filed in the U.S. District Court...
SAN CARLOS, Calif. , April 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that it has priced $250 million aggregate principal amount of convertible senior notes due 2027 (the "notes"). The notes will be sold to qualified institutional buyers pursuant to Rule 144A...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...